BASF’s April 30 Crossroads: A Spin-Off Vote, Q1 Earnings, and a Bullish Wall Street Call

Investors in BASF are bracing for a pivotal day on April 30, when the German chemical giant will deliver its first-quarter results and ask shareholders to approve the most radical restructuring in recent corporate history. The twin events come as one Wall Street analyst breaks with the consensus to predict a sharp turnaround ahead.

A Bold Bet from Citigroup

Just days before the earnings release, Citigroup analyst Sebastian Satz raised his price target on BASF to €61 from €55, reaffirming a “Buy” rating and placing the stock on a “positive catalyst watch” list. Satz argues that a “Goldilocks scenario” is emerging, with supply distortions in the market providing an operational tailwind. He identifies the second quarter of 2026 as the long-awaited inflection point for profit growth.

That view stands in stark contrast to the broader analyst community. The consensus price target sits at €52.25 — below the current share price of €54.24, which itself is less than one percent shy of the 52-week high of €54.70.

The stock gained roughly two percent on Thursday, marking its third attempt in recent weeks to break sustainably above the €55 resistance level. Since the start of the year, BASF shares have climbed more than 21 percent and are trading well above their key moving averages. However, the relative strength index (RSI) of 23.6 signals an oversold condition — a technical reading that typically points to short-term reversals rather than sustained buying pressure.

The Ag Spin-Off Vote

At the heart of the annual general meeting in Mannheim, which kicks off at 10:00 a.m. on April 30 — just three hours after the Q1 numbers land at 7:00 a.m. — shareholders will vote on spinning off the Agricultural Solutions division into a standalone subsidiary. The plan calls for an initial public offering in 2027.

Livio Tedeschi is set to take the helm of the new entity on May 1. BASF will remain the sole owner for the time being. Industry observers broadly support the move, noting that specialty chemicals and agrochemicals follow entirely different market cycles. A separation, they argue, gives both businesses more operational flexibility.

Should investors sell immediately? Or is it worth buying BASF?

Cost Cuts and Capacity Expansions

The quarterly report will serve as an early stress test for the company’s cost-saving program. A weak US dollar could weigh on operating earnings by as much as €200 million. At the same time, demand from Europe’s automotive and construction sectors remains sluggish.

For the full year, management is targeting operating earnings between €6.2 billion and €7.0 billion. The midpoint of that range falls slightly short of prior analyst forecasts. On the cost front, however, BASF is making headway: the company aims to reduce annual spending by €2.3 billion by the end of 2026.

Alongside the restructuring, BASF is expanding production capacity for specialty plastic additives at its sites in Lampertheim, Germany, and Pontecchio Marconi, Italy. These materials are designed to withstand extreme UV radiation and harsh weather, catering to rising demand for durable plastics.

Dividend and Buyback Plans

Shareholders will also vote on the proposed dividend of €2.25 per share. The company has been running a share buyback program, having already repurchased nearly €800 million worth of its own stock by mid-March. Analysts, meanwhile, expect a dividend of €2.28 per share for the current year, up from the €2.25 payout for 2025.

In the fourth quarter of 2025, BASF reported revenue of €14.03 billion — a significant decline year-on-year, though the company managed to exit the loss zone operationally. Whether that trend continues in the Q1 report will either bolster Citigroup’s bullish thesis or put it under pressure.

For now, the market appears to be betting on a positive outcome. If shareholders approve the restructuring plans on April 30, the stock could quickly test its 52-week high — and perhaps challenge the €55 barrier that has so far proven elusive.